Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Q4 2023 Earnings Call Transcript

Monogram Orthopaedics, Inc. (NASDAQ:MGRM) Q4 2023 Earnings Call Transcript March 21, 2024

Monogram Orthopaedics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Benjamin Sexson: Okay, great. Thanks Greg. Well, good afternoon, everybody. We really appreciate you joining us today for this Update Call. I want to try and lay a couple of ground rules from the start. We're going to be really collaborative on this. You're going to be able to chat with us. There's a chat on the right-hand side of your screen, and we will be looking at that and doing our best not to -- it's going to be a free speech platform, so please keep it respectful. Please no bad language, nothing obvious -- obviously kind of unconstructive. But as a management team, we really want to be as open and available as we possibly can and give everybody an update on how everything is doing and go from there. So, we're going to start out with a -- and I should introduce the team.

So, on the left, I don't know if it's in the same order for our viewers, but my name is Ben Sexson, I'm the CEO of Monogram Orthopaedics. Directly below me on the left there is Noel, maybe Noel you can wave to the audience, Noel Knape, our CFO. We have our CTO, Kamran Shamaei below him; and then Dr. Unis, our Founder, who is still a practicing orthopedic surgeon, and we got him out of the operating room for this call. So, with that, I'm going to turn it over to Noel to just mention some of the disclaimers about forward-looking statements and then we'll jump into the call.

An orthopedic surgeon performing a surgery while using ankle plating systems.

Noel Knape: Thanks Ben. Good afternoon everybody. Just some little housekeeping here. I want to go over the forward-looking statements disclaimer with you before we get started in this presentation, we're really excited to give. As a legal disclaimer, this presentation by Monogram Orthopaedics, Monogram may include forward-looking statements. To the extent that information presented in this presentation discussed as financial projections, information or expectations about Monogram's business plans, results of operations, products or markets or otherwise, make statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words as they should, may, intends, anticipates, believes, estimates, projects, forecasts, expects, plans, goal, target, and proposes.

Although Monogram believes that the expectations reflected in this presentation are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. So, no one has a crystal ball.

Benjamin Sexson: Terrific. Thanks Noel. Appreciate it. So, the presentation is going to cover these five topics. We're going to start with a quick financial summary. We're going to get into a detailed regulatory strategy review, give you some market analysis and just an overview of where we are. We'll have, hopefully, Dr. Unis to kind of speak from a surgeon's perspective on our product. And then from there, we're going to open it up to a Q&A. And if you have questions, please type them in the right, and we will be doing our best to get to kind of the majority of those. So, with that, Noel, why don't you kick it off?

See also 40 Best Perfumes for Women of 2024 and 13 States with the Most Fatal Accidents in the US.

To continue reading the Q&A session, please click here.